Survival has increased substantially for young women with breast cancer since 1975, though it has largely reached a plateau since around 2005.
CX-01, a low-anticoagulant heparin derivative, has demonstrated good rates of complete remission, rapid platelet recovery, and no serious adverse events.
A dose-dense neoadjuvant chemotherapy regimen yielded higher response rates compared with a standard regimen in a cohort of bladder cancer patients.
In this article, we review the role of baseline tumor size in response and survival on traditional and contemporary therapies for the treatment of locoregional and distant melanoma recurrences.
A 57-year-old man presents with a history of pruritic rashes that have persisted over the last 6 months. What is your diagnosis?
This article summarizes the key side effects associated with ADT for the treatment of prostate cancer and discusses strategies to optimize management.
Retroperitoneal sarcoma is a rare tumor whose diagnosis and management can be challenging and for which management requires a multidisciplinary team.
A study shows expanding access to care through insurance has the potential to improve outcomes in adults with follicular lymphoma.
ONCOLOGY spoke with Eric Ko, MD, PhD, who recently published a review article with his colleagues on strategies for combining radiation therapy with immunotherapy for the treatment of non–small-cell lung cancer.
COUNTERPOINT: Should Radiation Therapy Be Routinely Used in the Adjuvant Treatment of Stage III Endometrial Cancer?
The routine use of adjuvant radiation therapy in stage III endometrial cancer patients is not supported by the current literature and should not be employed universally in this group of patients.
POINT: Should Radiation Therapy Be Routinely Used in the Adjuvant Treatment of Stage III Endometrial Cancer?
Adjuvant radiation therapy provides a local control benefit in stage III endometrial carcinoma patients, as strongly suggested in retrospective and prospective series.
In this article, we review the methods of determining cell of origin (COO); use of COO in clinical practice; clinical trials in DLBCL according to COO; and future directions of tailoring treatment, including alternate categorization of genetic subtypes or clusters in DLBCL.
In this article, we review the findings of the IDEA study and discuss the optimal duration of oxaliplatin-based adjuvant chemotherapy using patient-based risk factors.
Individuals who develop frequent basal cell carcinomas may have an increased prevalence of germline mutations in DNA repair genes and an increased malignancy risk.
Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.